Eosinophilic Oesophagitis: From Rare to Commonplace, What Are the Potential Explanations?

Eosinophilic Oesophagitis: From Rare to Commonplace, What Are the Potential Explanations?

December 1, 2016 at 8:23 AM 0 comments

*Russell J. Hopp Creighton University, Omaha, Nebraska, USA *Correspondence to RUSSELLHOPP@creighton.edu Disclosure: The author has declared no conflicts of interest. Received: 29.03.16 Accepted: 03.08.16 Citation: EMJ Gatstroenterol. 2016;5[1]:89-95. Abstract In this century, eosinophilic oesophagitis (EoE) has become a more recognised allergic disease, resulting in the publication of two consensus reportsRead More

Eosinophilic Oesophagitis: Current Understanding and Future Directions

Eosinophilic Oesophagitis: Current Understanding and Future Directions

December 1, 2016 at 8:22 AM 0 comments

Christopher Ma, *Eldon A. Shaffer Division of Gastroenterology, University of Calgary, Calgary, Alberta, Canada *Correspondence to shaffer@ucalgary.ca Disclosure: The authors have declared no conflicts of interest. Received: 08.08.16 Accepted: 25.10.16 Citation: EMJ Gastroenterol. 2016;5[1]:96-106. Abstract Eosinophilic oesophagitis (EoE) is an emerging disorder that manifests clinically with characteristic symptoms of oesophagealRead More

Infliximab and Tumour Necrosis Factor Alpha Measurement on Intestinal Mucosa: A New Tool for the Clinic?

Infliximab and Tumour Necrosis Factor Alpha Measurement on Intestinal Mucosa: A New Tool for the Clinic?

December 1, 2016 at 8:21 AM 0 comments

*Silvia Pecere,1 Valentina Petito,1 Arianna Amato,2 Andrea Poscia,3 Alessandro Armuzzi,1 Loris Riccardo Lopetuso,1 Alessandro Sgambato,4 Giovanni Cammarota,1 †Alfredo Papa,1 †Antonio Gasbarrini,1 †Franco Scaldaferri1 1. Internal Medicine Department, Gastroenterology Division, Catholic University of the Sacred Heart Rome, Rome, Italy 2. Institute of Anesthesia and Resuscitation, University of the Sacred Heart Rome, Rome, Italy 3.Read More

Barrett’s Oesophagus in 2016

Barrett’s Oesophagus in 2016

December 1, 2016 at 8:20 AM 0 comments

*Monjur Ahmed Division of Gastroenterology and Hepatology, Department of Internal Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania, USA *Correspondence to monjur.ahmed@jefferson.edu Disclosure: The author has declared no conflicts of interest. The views presented in this article are those of the author and do not necessarily reflect the policy of Thomas JeffersonRead More

Monoclonal Antibody-Based Therapy for Eosinophilic Oesophagitis

Monoclonal Antibody-Based Therapy for Eosinophilic Oesophagitis

December 1, 2016 at 8:19 AM 0 comments

*Garry M. Walsh School of Medicine, Medical Sciences and Nutrition, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK *Correspondence to g.m.walsh@abdn.ac.uk Disclosure: The author has declared no conflicts of interest. Received: 23.06.16 Accepted: 25.08.16 Citation: EMJ Gastroenterol. 2016;5[1]:125-129. Abstract Eosinophilic oesophagitis is an inflammatory condition associated with marked eosinophilRead More

How to Improve Your Success in Treating Mild and Moderate Inflammatory Bowel Disease

How to Improve Your Success in Treating Mild and Moderate Inflammatory Bowel Disease

May 12, 2016 at 8:30 AM 0 comments

Summary of presentations from the Tillotts Pharma-sponsored Satellite Symposium on Inflammatory Bowel Disease, held in Amsterdam, Netherlands, on 18th March 2016 Chairperson: Geert D’Haens1 Speakers: Ailsa Hart,2 Pieter Hindryckx3 1. Academic Medical Centre-IBD Unit, University of Amsterdam, Amsterdam, Netherlands 2. Director, IBD Unit, St Mark’s Hospital, London, UK 3. ResearchRead More

Beyond the Gut: The Importance of Controlling Systemic Inflammation in Inflammatory Bowel Disease

Beyond the Gut: The Importance of Controlling Systemic Inflammation in Inflammatory Bowel Disease

May 6, 2016 at 8:30 AM 0 comments

Summary of presentations from the AbbVie-Sponsored Symposium on Inflammatory Bowel Disease, held at the 11th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Amsterdam, Netherlands, on 17th March 2016 Chairperson: Geert D’Haens1 Speakers: Yehuda Chowers,2 Remo Panaccione,3 Geert D’Haens1 1. Academic Medical Centre-IBD Unit, University of Amsterdam, Amsterdam,Read More

In It for the Long Haul: Managing the Complexity of Crohn’s Disease

In It for the Long Haul: Managing the Complexity of Crohn’s Disease

April 29, 2016 at 9:10 AM 0 comments

Summary of presentations from the Takeda-Sponsored Symposium held on at the 11th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Amsterdam, Netherlands, on 18th March 2016 Chairperson: Michael A. Kamm1 Speakers: Michael A. Kamm,1 Remo Panaccione,2 Stefan Schreiber3 1. St Vincent’s Hospital, Melbourne, Australia 2. Inflammatory Bowel Disease Group, UniversityRead More

Management of Ulcerative Colitis: Putting Patients at the Centre

Management of Ulcerative Colitis: Putting Patients at the Centre

April 29, 2016 at 9:03 AM 0 comments

Summary of presentations from the Takeda-sponsored symposium at the 11th Congress of the European Crohn’s and Colitis Organisation, held in Amsterdam, Netherlands on 18th March 2016 Chairperson: Iris Dotan1 Speakers: Peter Irving,2 David T. Rubin3 1. Tel Aviv Sourasky Medical Center and the Sackler School of Medicine, Tel Aviv, Israel 2. Guy’s and StRead More

Regorafenib in Advanced and Refractory Gastrointestinal Cancers

Regorafenib in Advanced and Refractory Gastrointestinal Cancers

April 5, 2016 at 8:57 AM 0 comments

*Ewen D. Legg Halcyon Medical Writing LTD., Thurso, UK *Correspondence to ewen.d.legg@gmail.com Disclosure: Medical writing assistance was funded by Bayer. Received: 08.02.16 Accepted: 09.03.16 Citation: EMJ. 2016;1[2]:18-25. Abstract The American Society of Clinical Oncology’s 2016 Gastrointestinal Cancer Symposium (ASCO-GI), held in San Francisco, California, USA, provided a forum for leadingRead More